Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations
Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, announced the appointment of Donna Rill as Chief Technology Officer. As CTO, Rill will use her extensive technology development and manufacturing experience to help drive Triumvira’s clinical development programs.
Ms. Rill is an accomplished expert in cellular therapy manufacturing and has held responsibility for the design and qualification of cell and gene therapy laboratories using novel technologies, as well as production, service and research type laboratories. In addition to her construction, project management and regulatory/quality assurance and control knowledge, she brings extensive operational and strategic experience in cell and gene therapy, and antibody and protein production.
Paul Lammers, MD, MSc., President and CEO of Triumvira Immunologics commented, “As we continue our progress in leveraging the results of strong anti-tumor activity in in vitro and xenograft models, we look forward to utilizing Donna’s deep operational and technology experience in bringing our TAC product candidates into clinical development and ultimately towards commercialization.”
Ms. Rill’s earlier positions include Vice President of Manufacturing for Cell Medica, Chief Development Officer for Opexa Therapeutics, Laboratory Director of Cell and Gene Therapy at Baylor College of Medicine (Head: Prof. Malcolm Brenner); and Lab Manager of the GMP Cell & Gene Therapy Laboratories at St. Jude Children’s Research Hospital.
“I am excited to join this growing team and use my technology development and manufacturing expertise to bring Triumvira’s TAC technology into clinical development,” Ms Rill said. “The company’s novel science and technology combined with a best-in-class team hold real promise for helping to develop better T cell therapies for a broader range of patients with cancer and other diseases.”